Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 43,915	$ 55,516
Short-term investments – available for sale	898,348	306,563
Prepaid clinical trial and preclinical study costs	3,323	2,624
Prepaid expenses and other current assets	138	2,522
Total current assets	945,724	367,225
Right-of-use assets	977	1,126
Deferred financing costs	105	106
Deposits	33	33
Total assets	946,839	368,490
Current liabilities:
Accounts payable	11,090	7,512
Other accrued liabilities	13,669	11,299
Lease liability, current	334	324
Total current liabilities	25,093	19,135
Lease liability, net of current portion	766	936
Total long-term liabilities	766	936
Total liabilities	25,859	20,071
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at June 30, 2024 and December 31, 2023; no shares issued and outstanding at June 30, 2024 and December 31, 2023
Common stock, $0.00001 par value: 300,000,000 shares authorized at June 30, 2024 and December 31, 2023; 110,796,200 shares issued and outstanding at June 30, 2024 and 100,113,770 shares issued and outstanding at December 31, 2023	1	1
Treasury stock at cost, no shares at June 30, 2024 and 2,193,251 shares at December 31, 2023	0	(6,795)
Additional paid-in capital	1,350,801	733,546
Accumulated deficit	(427,550)	(377,944)
Accumulated other comprehensive loss	(2,272)	(389)
Total stockholders’ equity	920,980	348,419
Total liabilities and stockholders’ equity	$ 946,839	$ 368,490